Statins prevent cancer in heart transplant recipients

May 20, 2012

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

The research was presented at the Heart Failure Congress 2012, 19-22 May, in Belgrade, Serbia. The Congress is the main annual meeting of the Association of the European Society of Cardiology.

Cancer is the leading cause of death late after heart transplantation. is particularly common, but solid organ cancers including colorectal cancer, and lymphoma also occur. The increased rate of cancer in may be related to the of the patient.

Statins are immunomodulatory drugs and may benefit patients beyond their lipid lowering effects. The current study (abstract P306) investigated the impact of statin therapy on the occurrence of cancer and death from all causes in heart transplantation recipients.

The study included all 255 patients who underwent heart transplantation at the University Hospital Zurich in Switzerland between 1985 and 2007 and were alive after the first year. The primary endpoint was the occurrence of any cancer and the secondary endpoint was overall survival.

During follow up, cancer was diagnosed in 108 patients (42%). Statins reduced the risk of any cancer by 65% (p=0.0001). Eight years after transplantation the cumulative incidence of tumours was 34% in patients not receiving a statin compared to 13% in patients receiving a statin (p=0.003). The benefit persisted at the 10 year (39% vs. 18%) and 12 year follow-up (42% vs. 22%).

Statin use was associated with improved cancer free and overall survival (both p=0.0001). The of statins on preventing cancer and reducing death from all causes was independent of patients' . This suggests that the benefit of statins was due to their immunomodulatory effects.

Guidelines from the International Society for Heart & Lung Transplantation (ISHLT) recommend giving a statin to patients after to reduce graft atherosclerosis. This study shows that there are additional benefits to following that recommendation.

Lead author Dr Frank Enseleit, deputy director of heart failure and transplantation at University Hospital Zurich, says patients can safely begin statin therapy six months after transplantation and they should take the drug for the rest of their lives.

"We have shown that statin therapy prevents cancer in heart transplant recipients and it is known that statins also prevent graft atherosclerosis," he says. "We have to conclude that it should be a lifelong therapy in heart transplant recipients."

Explore further: Study finds no link between statins and cancer risk

Related Stories

Study finds no link between statins and cancer risk

July 25, 2011

(Medical Xpress) -- A new study published in the Journal of the American College of Cardiology reports that, contrary to previous studies, the use of cholesterol reducing statin drugs does not increase the risk of patients ...

Recommended for you

Study identifies key player in heart enlargement

June 27, 2017

The heart is a dynamic muscle that grows and shrinks in response to stressors such as exercise and disease. The secret to its malleability lies in individual cells, which get bigger or smaller depending on the heart's needs. ...

Mechanism shown to reverse disease in arteries

June 26, 2017

A certain immune reaction is the key, not to slowing atherosclerosis like cholesterol-lowering drugs do, but instead to reversing a disease that gradually blocks arteries to cause heart attacks and strokes.

Where are the new therapies for heart disease?

June 26, 2017

Despite dramatic reductions in the death rate from cardiovascular disease, which includes heart disease and stroke, it remains the leading causes of death, and experts have expressed concern that the number of new therapies ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.